National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Economic evaluation of Boceprevir (Victrelis®) as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
19/08/2011 17/01/2012 Reimbursement Recommended

We consider boceprevir a highly cost-effective therapy when added to peginterferon-ribavirin for the treatment of patients infected with genotype 1 hepatitis C virus in the Irish healthcare setting

 Boceprevir (Victrelis®) summary